Asieris Receives the TGA’s Approval to Initiate P-I Trial for APL-2301 to Treat Acinetobacter baumannii Infection
Shots:
- Asieris Pharma’s subsidiary, MetCure Pharma has received the TGA’s approval to initiate a P-I clinical trial for APL-2301, which was formerly known as ASN-1733 & was marketed as MET-102 for the treatment of Acinetobacter baumannii infections
- The P-I clinical trial is expected to evaluate the safety, tolerability & of APL-2301 in patient with Acinetobacter baumannii infections. The study is planned to evaluate the PK characteristics of a single/multiple doses of APL-2301 & the effect of food-drug interaction on the drug’s absorption & systemic exposure in healthy volunteers
- APL-2301 is a FIC small molecule that under preclinical evaluation depicted significant antimicrobial activity against various clinically isolated Acinetobacter baumannii incl. CRAB
Ref: Asieris | Image: Asieris
Related News:- Asieris Reports P-III Bridging Trial of Hexvix for the Treatment of Bladder Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
